Adjuvant sodium clodronate, a first-generation bisphosphonate, showed no benefit in patients with nonmetastatic prostate cancer in a recent randomized, double-blind, placebo-controlled trial.

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

Alphen aan den Rijn [Netherlands], April 17 (ANI): Combining chemotherapy and hormonal therapy for patients with locally advanced prostate cancer provides longer control of prostate-specific ...

“Our study revealed that approximately 30% to 35% of nearly 16,000 men in the United Kingdom with high-risk localized or locally advanced prostate cancer did not receive potentially curative ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A Dundalk-area man is the first person in Canada to receive a new, publicly funded treatment that better targets prostate cancer cells and is shown to prolong life.

According to GlobalData, Phase II drugs for Androgen-Sensitive Prostate Cancer does not have sufficient historical data ... It is also indicated as a second- or third-line treatment for patients with ...

An innovative drug trialled for tackling certain cancers holds potential benefits for advanced prostate cancer patients whose current treatments have failed, scientists say. The breakthrough has ...

Advanced imaging reveals hidden metastases in high-risk prostate cancer cases, offering new insights for better diagnosis and treatment strategies. Many cases of high-risk nonmetastatic hormone ...

The addition of Truqap to standard-of-care therapy improved radiographic progression-free survival in patients with ...